From Pixels to Pills: Unleashing the Power of the Digital Revolution
Since the start of the digital revolution, Pfizer has been at the forefront of integrating digital technologies into its drug development and research processes. By embracing computer-aided drug design and employing high-throughput screening techniques—methods that rapidly test numerous chemical compounds or biological substances against specific targets— Pfizer has pioneered new approaches in pharmaceutical R&D. The company led the way in the use of predictive modelling and data analytics, harnessing big data to uncover valuable insights and optimize drug development pathways. This proactive approach to leveraging digital tools not only enhanced Pfizer's R&D efficiency but also positioned the company as a trailblazer in the pharmaceutical industry's digital transformation.
Our Center for Digital Innovation (CDI) in Thessaloniki showcases the company's commitment to leveraging digital technologies in healthcare. Situated in a vibrant tech ecosystem, the hub harnesses data analytics, AI, and digital platforms to advance drug discovery and patient care. This strategic initiative not only underscores Pfizer's dedication to staying at the forefront of healthcare innovation but also stimulates economic growth in the region. With a focus on collaboration and talent development, the CDI serves as a pivotal centre for driving transformative digital capabilities within Pfizer and beyond.
Given our extensive presence in Europe, we closely follow legislative developments that could impact our operations and future investments across the continent. The European Health Data Space (EHDS) presents a significant opportunity for all stakeholders in the healthcare sector to contribute to a unified European ecosystem for data sharing.
The EHDS primarily focuses on empowering patients by allowing them to better manage their health data, which would in turn facilitate cross-border healthcare access for all EU citizens. Pfizer’s primary focus lies in the secondary use of data, specifically in the re-use of data for research, innovation, and policymaking, and we have actively engaged with policymakers throughout the legislative procedure.
We have also monitored the approval of the AI Act by European legislators. While we endorse the overarching goals of the AI Act, we, along with others in the industry, question whether a broad legislative approach is suitable for governing AI within the already highly regulated healthcare sector. Following our engagement on the EMA public consultation on the Reflection Paper on AI, it will be essential to ensure consistency between the forthcoming EMA Guidance on AI and the AI Act.
In conclusion, Pfizer is at the forefront of digital innovation and supports legislative efforts aimed at ensuring a predictable and effective regulation of emerging technologies. Through its dedication to responsible progress, Pfizer envisions a future where healthcare embraces technological advancements, offering hope for a better tomorrow for all.